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ABSTRACT
During the six-month collection period, 284 bacterial strains were recovered from different clinical 
samples from cats and dogs. Susceptibility to cefovecin was determined by disk-diffusion method. Out of 284 
bacterial isolates, 202 were gram-positive bacteria and 82 were gram-negative. The most frequently isolated 
bacterial species was gram-positive Staphylococcus pseudintermedius (152), followed by streptococci (50). 
The most common gram-negative bacteria were Pseudomonas aeruginosa (26), Proteus spp. (25) and E. coli 
(22). The highest resistance among gram-positive bacteria was observed in non-hemolytic streptococci (50%) 
and Staphylococcus pseudintermedius (7.2%). Beta-hemolytic streptococci were 100% sensitive to cefovecin. 
As expected, cefovecin did not show any activity against P. aeruginosa. Besides that, the highest resistance 
was shown by E. coli (40.9%) and Proteus spp. (8%). All P. multocida isolates were sensitive to cefovecin. The 
results of the conducted survey show no signifi cant differences of cefovecin activity against beta-hemolytic 
streptococci and P. multocida isolates from EU and USA compared to Croatian strains, when tested by the broth 
microdilution and disk-diffusion method. However, resistance rates in S. pseudintermedius, E. coli and Proteus 
spp. are much higher among the Croatian strains.
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Introduction
Cephalosporins are widely used in veterinary medicine based on their broad 
spectrum activity and safety. They are used for the treatment of bacterial infections of 
the skin, urinary and genital tracts, respiratory tract, infections of bones and joints, soft 
tissues as well as prophylactic use in abdominal surgery (GREENE and WATSON, 2001). 
Many antimicrobial agents require administration at least twice a day for at least seven 
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days, some even more often and for a longer period (several weeks) depending on the 
antimicrobial agent and affected organ. Furthermore, some cephalosporin antibiotics are 
only available for parenteral administration so the owner has to go to a clinic every day, 
which causes additional stress for the animal and increases the cost of treatment. 
Cefovecin (Convenia®, Pfi zer Animal Health) is a new third-generation cephalosporin 
antibiotic approved for use in cats and dogs since 2006 in EU and 2008 in USA. The 
drug has a very long half-life, so that a single injection lasts 14 days in cats and dogs. 
Cefovecin differs from other cephalosporins in that it is highly protein bound and has 
a long duration of activity (STEGEMANN et al., 2006b; STEGEMANN et al., 2006c). As 
with all cephalosporins, the bactericidal action of cefovecin results from the inhibition 
of bacterial cell wall synthesis. The major benefi t of cefovecin is its long duration of 
activity. The product is well tolerated and has minor side effects (PASSMORE et al., 2007; 
PASSMORE et al., 2008; STEGEMANN et al., 2007a; STEGEMANN et al., 2007b).
The objective of this study was to determine the in vitro activity of cefovecin against 
different gram-positive and gram-negative aerobic bacteria isolated from samples from 
different pathological conditions in cats and dogs. The main purpose of this investigation 
was to obtain an overview of the susceptibility of most common aerobic bacteria isolated 
from animals to cefovecin. We considered such a survey important because the use of 
cefovecin in Croatia began just recently, after its approval in 2008. 
Materials and methods
In a six-month period specimens originating from cats and dogs visiting The Clinics of 
the University of Zagreb Veterinary Faculty were submitted to microbiological examination 
and a total of 284 different bacterial strains were isolated. Bacterial strains were isolated 
from: the external ear canal (133), skin (61), urine (21), throat (18), conjunctival sac (13), 
nostrils (11), infected wounds (9), genital tract (10), interdigital area (6), and rectum 
(2). Identifi cation of isolated bacteria was carried out according to procedures described 
by QUINN et al. (1994; 2002). In the present study, 284 bacterial isolates were tested on 
Mueller-Hinton agar for antimicrobial susceptibility to cefovecin by the Kirby-Bauer’s 
disk-diffusion method recommended by the Clinical and Laboratory Standards Institute 
(ANONYM., 2008). Disks (Pfi zer Animal Health) with 30 μg of cefovecin were used. 
The following pathogens were tested: Staphylococcus (S.) pseudintermedius (formerly 
identifi ed as S. intermedius) (n = 152), non-hemolytic Streptococcus spp. (n = 28), beta-
hemolytic Streptococcus spp. (n = 22), P. aeruginosa (n = 26), E. coli (n = 22), Proteus 
spp. (n = 25) and P. multocida (n = 9). E. coli ATCC 25922 and S. aureus ATCC 25923 
were used as control strains (the diameter of inhibition zone around 30 μg cefovecin disk 
was 26 and 30 mm, respectively).
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The culture was incubated for 18-24 hours at 37 °C. The zone of inhibition around disk 
was measured, and the measurement compared to a data presented in Table 1, that classify 
the organism into three categories: sensitive, resistant and intermediate sensitive.
Results
The antimicrobial susceptibility testing results of all isolated bacteria are presented 
in Table 2. Out of 284 bacterial isolates 202 isolates were gram-positive bacteria and 82 
were gram-negative. The most frequently isolated bacterial species was gram-positive 
S. pseudintermedius (152) and 141 strains (92.8%) were susceptible to cefovecin. 
Streptococci were, beside S. pseudintermedius, most often isolated gram-positive bacteria. 
Out of 50 isolated strains, 28 were non-hemolytic and 22 strains were β-hemolytic. 
Interestingly, the highest resistance to cefovecin was present in non-hemolytic strains, 
where 14 strains (50%) were resistant. β-hemolytic streptococci were 100% sensitive to 
cefovecin. 
Table 1. MIC and zone diameter interpretive criteria for cefovecin (as proposed in Convenia 
Injectable Lyophile (Canada)® package insert)
MIC and zone diameter (30 μg disk) interpretive chart for cefovecin
MIC (μg/mL) Zone diameter (mm) Interpretation
≤2 ≥ 23 susceptible (S)
4 20-22 intermediate (I)
≥ 8 ≤19 resistant (R)
Table 2. Antimicrobial susceptibility to cefovecin in 284 clinical isolates tested by disk-diffusion 
method
Bacteria
S I R Total 
numberNo % No % No %
Gram - positive  
Staphylococcus pseudintermedius 141 92.8 0 0 11 7.2 152
Streptococcus spp. (non-hemolytic, 
including enterococci) 14 50 0 0 14 50 28
Streptococcus spp. ß-hemolytic 22 100 0 0 0 0 22
Total 202
Gram - negative
Pasteurella multocida 9 100 0 0 0 0 9
Proteus spp. 23 92 0 0 2 8 25
Escherichia coli 13 59.1 0 0 9 40.9 22
Pseudomonas aeruginosa 0 0 0 0 26 100 26
Total 82
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All 26 P. aeruginosa isolates were resistant to cefovecin. Proteus spp. was isolated 25 
times and 23 strains (92.0%) were sensitive and two (8%) were resistant. Out of 22 E. coli 
isolates 13 (59.1%) were sensitive and 9 (40.9%) strains were resistant. All P. multocida 
isolates were sensitive to cefovecin.
Discussion
Cefovecin (Convenia®, Pfi zer Animal Health) is a new extended-spectrum 
cephalosporin that was introduced in small animal practice in Croatia in year 2008. The 
antimicrobial activity of cefovecin is similar to the other cephalosporin antibiotics, which 
share a low toxicity and good activity against many gram-positive and gram-negative 
aerobic bacteria. Cephalexin’s in-vitro activity was previously tested in parallel to cefovecin 
investigating more than 2,600 isolates (STEGEMANN et al., 2006a). Unfortunately, very 
few papers on this subject are available and it is diffi cult to discuss results obtained in 
this study. However, STEGEMANN et al. (2006a) investigated antimicrobial susceptibility 
to cefovecin in 2641 bacterial strains isolated from dogs and cats. Bacterial isolates from 
different European countries and USA were predominantly Staphylococcus intermedius, 
E. coli, Pasteurella multocida, and Proteus mirabilis. MIC determination was performed 
for cefovecin, cephalexin, cefadroxil and amoxicillin-clavulanic acid. Although clinical 
breakpoints for cefovecin have not yet been submitted to CLSI, the criteria presented 
in Table 1, proposed in the package insert of Convenia Injectable Lyophile (Canada)® 
(Pfi zer Animal Health, Pfi zer Canada Inc.), were used.
According to the results of STEGEMANN et al. (2006a) cefovecin exhibited good in vitro 
activity against 501 S. intermedius USA and European isolates with MIC90 value of 0.25 
μg/mL. Five isolates (<1%) had MIC values ≥8 μg/mL and were considered resistant. In 
our study, 11 (7.2%) isolates of S. pseudintermedius were resistant to cefovecin which is a 
much higher resistance rate. Five of them were mecA positive and considered methicillin-
resistant.
Interestingly, the highest resistance to cefovecin was present in non-hemolytic 
streptococci, where, out of 28 isolates 14 (50%) were resistant. As they were not 
identifi ed to the species level, the reason for such high resistance might be the possibility 
that a large proportion of them were actually enterococci. STEGEMANN et al. (2006a) 
determined that MIC90 for Enterococcus spp. was >32 μg/mL, so more than 90% of 
isolates in that study can be considered resistant to cefovecin. In our study no resistance 
was noted among β-hemolytic streptococci, which is in complete agreement with previous 
fi ndings (STEGEMANN et al., 2006a). This is very important, because it is well known that 
Streptococcus canis, a very common inhabitant of dog’s skin, and a frequent cause of 
vaginitis, pyoderma and otitis externa, is β-hemolytic. 
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Among the gram-negative bacterial isolates, there was no resistance in P. multocida, 
in general sensitive to the majority of antimicrobial agents. This is in agreement with 
the results obtained by STEGEMANN et al. (2006a), where all 381 strains tested exhibited 
MICs of ≤2 μg/mL, which means they were all sensitive to cefovecin. A slightly different 
result was obtained with Proteus spp., where, out of 25 isolates tested, 23 were sensitive 
(92%) and two strains (8%) were resistant. STEGEMANN et al. (2006a) found only one 
Proteus sp. resistant strain out of 71 tested isolates, which is a much lower rate than 
determined in this study (8%). Among the 22 E. coli strains, isolated mainly from dogs 
with urinary tract infections, 40.9% were resistant, compared to less than 2% determined 
by STEGEMANN et al. (2006a). The majority of resistant E. coli isolates in our study were 
also resistant to amoxicillin-clavulanic acid and cephalexin, probably because of the 
production of extended spectrum beta-lactamase. The reason for such a high resistance 
rate in our study might be previous treatment with antimicrobials, which was noted in 
most of dogs with UTI.
Lastly, besides having intrinsic resistance to I and II generation cephalosporins, 
all Pseudomonas aeruginosa isolates were also resistant to cefovecin, which confi rms 
previous fi ndings (STEGEMANN et al., 2006a).
The results of the survey conducted show no signifi cant differences in cefovecin 
activity against beta-hemolytic streptococci and P. multocida isolates from the EU and 
USA compared to Croatian strains, when tested by broth microdilution and disk-diffusion 
methods. However, resistance rates in S. pseudintermedius, E. coli and Proteus spp. are 
much higher among the Croatian strains. The reason might be that cefovecin was already 
on the market for at least one year before the beginning of this study. Also, isolates tested 
in the study by STEGEMANN et al. (2006a) were collected between 1999 and 2003, which 
is fi ve to nine years earlier. Many of the isolates in our study are from problematic cases 
that were previously empirically treated with antimicrobials until samples were submitted 
to our laboratory for culture and susceptibility testing. 
_______
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SAŽETAK
Tijekom šestomjesečnog razdoblja 284 izolata bakterija izdvojena su iz različitih kliničkih uzoraka 
podrijetlom od pasa i mačaka. Osjetljivost sojeva na cefovecin određena je disk-difuzijskom metodom. Od 284 
izolata 202 bila su gram-pozitivne, a 82 gram-negativne bakterije. Najzastupljenija je bila vrsta Staphylococcus 
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pseudintermedius (152), a na drugom mjestu streptokoki (50). Najčešće gram-negativne vrste bile su 
Pseudomonas aeruginosa (26), Proteus spp. (25) i E. coli (22). Najviša stopa rezistencije među gram-pozitivnim 
bakterijama utvrđena je u nehemolitičkih streptokoka (50%) i u vrste Staphylococcus pseudintermedius (7,2%). 
Beta-hemolitički streptokoki bili su 100% osjetljivi na cefovecin. Kao što je bilo očekivano, cefovecin nije 
bio djelotvoran na vrstu P. aeruginosa. Vrlo visok postotak rezistentnih sojeva utvrđen je i kod vrsta E. coli 
(40,9%) i Proteus spp. (8%). Svi izolati P. multocida bili su osjetljivi na cefovecin. Ovi rezultati u skladu su s 
onima dobivenim određivanjem osjetljivosti beta-hemolitičkih streptokoka i sojeva P. multocida podrijetlom iz 
SAD-a i Europske Unije mikrodilucijskom metodom. To se ne može reći za izolate S. pseudintermedius, E. coli 
i Proteus spp., u kojih je utvrđen znatno viši postotak otpornih sojeva.
Ključne riječi: cefovecin, antimikrobni lijekovi, disk-difuzijska metoda, Staphylococcus pseudintermedius, 
E. coli, Proteus spp.
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